As per the aforementioned preclinical studies, the combined blockade of TIGIT and other immune checkpoints, specifically PD-1/PD-L1, appears to be able to overcome the limitations of single agent therapy, and even has the potential to result in complete tumor regression with the induction of a durable anti-tumor immune memory response [60,73,74]. This evidence concerns the gene TIGIT and neoplasm.